• 1. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Recent Advances in the Study of 2,3-Difluoro-N'-Hydroxybenzenecarboximidamide (CAS: 885957-13-1)

2,3-Difluoro-N'-hydroxybenzenecarboximidamide (CAS: 885957-13-1) is a compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have focused on its potential applications as a pharmacophore in drug discovery, particularly in the development of novel enzyme inhibitors and antimicrobial agents. This research brief synthesizes the latest findings related to this compound, highlighting its chemical properties, biological activities, and therapeutic potential.

One of the key areas of investigation has been the role of 2,3-difluoro-N'-hydroxybenzenecarboximidamide as a hydroxamic acid derivative, which is known for its ability to chelate metal ions. This property makes it a promising candidate for the inhibition of metalloenzymes, such as histone deacetylases (HDACs) and matrix metalloproteinases (MMPs). Recent in vitro studies have demonstrated its efficacy in modulating enzyme activity, with potential implications for cancer therapy and inflammatory diseases.

In addition to its enzyme inhibitory properties, 2,3-difluoro-N'-hydroxybenzenecarboximidamide has been explored for its antimicrobial activity. A 2023 study published in the Journal of Medicinal Chemistry reported that this compound exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including drug-resistant strains. The mechanism of action appears to involve disruption of bacterial cell wall synthesis, although further studies are needed to elucidate the precise molecular targets.

The synthesis and optimization of 2,3-difluoro-N'-hydroxybenzenecarboximidamide derivatives have also been a focus of recent research. Advances in synthetic chemistry have enabled the development of analogs with improved pharmacokinetic properties, such as enhanced solubility and bioavailability. Computational modeling and structure-activity relationship (SAR) studies have played a crucial role in guiding these efforts, identifying key structural features that contribute to the compound's biological activity.

Despite these promising findings, challenges remain in the clinical translation of 2,3-difluoro-N'-hydroxybenzenecarboximidamide. Issues such as metabolic stability, toxicity, and selectivity need to be addressed through further preclinical studies. Collaborative efforts between academic researchers and pharmaceutical companies are essential to overcome these hurdles and advance the compound toward clinical trials.

In conclusion, 2,3-difluoro-N'-hydroxybenzenecarboximidamide (CAS: 885957-13-1) represents a versatile scaffold with significant potential in drug discovery. Its dual role as an enzyme inhibitor and antimicrobial agent underscores its therapeutic value, while ongoing research continues to refine its properties and applications. Future studies should focus on optimizing its pharmacological profile and exploring its efficacy in vivo, paving the way for its eventual use in clinical settings.

• 880874-38-4(Benzenecarboximidamide, 2-fluoro-N,4-dihydroxy-)
• 175277-86-8(4-fluoro-N'-hydroxy-3-methylbenzene-1-carboximidamide)
• 764648-43-3(2,4,5-Trifluorobenzamidine hydrochloride)
• 885957-32-4(2,5-DIFLUORO-N-HYDROXY-BENZAMIDINE)
• 71204-93-8(2-Fluorobenzamidine)
• 690632-34-9(2,4,5-trifluoro-N'-hydroxybenzenecarboximidamide)
• 885957-28-8(2,5-Difluoro-benzamidine)
• 791070-86-5(Benzenecarboximidamide, 2,6-difluoro-N-hydroxy-N-methyl-)
• 885957-09-5(2,3-difluorobenzene-1-carboximidamide)
• 885954-65-4(2,3,4-trifluorobenzene-1-carboximidamide)